Fredun Pharmaceuticals has issued 3,61,599 fully paid-up equity shares following the conversion of 1,20,533 outstanding warrants. This equity expansion involves 10 non-promoter investors, including Alchemy Capital Management. The move follows a previous bonus issue adjustment.
Fredun Pharmaceuticals Issues 3.61 Lakh New Shares
1,20,533 warrants converted into 3,61,599 equity shares at Rs 10 face value.
Reader Takeaway: Capital base expansion follows conversion; dilution impact is modest given non-promoter participation.
What just happened
Fredun Pharmaceuticals has officially converted 1,20,533 outstanding warrants into 3,61,599 fully paid-up equity shares. The board approved this allotment on September 16, 2026. The new shares will carry a face value of Rs 10 each and will rank pari passu with existing company equity.
Why this matters
The conversion process confirms the inflow of capital from warrant holders. These warrants were originally issued on December 29, 2025, at Rs 1,250 each. A subsequent 1:2 bonus issue required a technical adjustment, resulting in each warrant now being exercisable into three equity shares upon payment of the balance consideration.
Allottees Overview
The company allotted these shares to 10 non-promoter entities. Notable participants include Alchemy Capital Management and Alchemy Long Term Ventures Fund. Other recipients include Ajay Kumar Aggarwal, Swati Goel, and Nav Ratan Bhaiya. All shares are issued in dematerialized form.
Risks to watch
Investors should note the equity dilution resulting from the issuance of over 3.6 lakh new shares. While the allotment is limited to non-promoters, market participants often track the exit strategies of such institutional and individual investors following allotment.